Literature DB >> 17113075

Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats.

Matthias E Liechti1, Athina Markou.   

Abstract

Stimulatory actions of nicotine on mesocorticolimbic dopamine transmission are partly mediated by nicotine-induced glutamate release acting on ionotropic and metabotropic glutamate (mGlu) receptors. Because both presynaptic inhibitory mGlu2/3 and postsynaptic excitatory mGlu5 receptors provide potential targets for treatment of aspects of nicotine dependence, we examined interacting effects of mGlu5 (2-methyl-6-(phenylethynyl)-pyridine, MPEP) and mGlu2/3 (LY341495) receptor antagonists on nicotine self-administration and brain reward threshold elevations associated with spontaneous nicotine withdrawal in rats. We hypothesized that increasing glutamate transmission by blocking presynaptic inhibitory mGlu2/3 autoreceptors would antagonize MPEP-induced decreases in nicotine self-administration. We also hypothesized that blocking postsynaptic actions of glutamate on mGlu5 receptors would exacerbate nicotine withdrawal-induced reward deficits, and that this effect would be attenuated by co-administration of the mGlu2/3 receptor antagonist LY341495. MPEP selectively decreased nicotine, but not food, self-administration in rats. LY341495 slightly decreased both nicotine and food self-administration. Co-administration of LY341495 with MPEP attenuated the effectiveness of MPEP in decreasing nicotine intake, although MPEP was still effective. Spontaneous nicotine withdrawal induced somatic signs of withdrawal and reward threshold elevations indicating reward deficits. MPEP increased somatic signs and reward deficits in both nicotine- and saline-withdrawing rats. Thus, while mGlu5 receptor antagonists may be therapeutically useful in decreasing tobacco smoking, they worsen nicotine withdrawal. Co-administration of LY341495 reduced MPEP-induced reward deficits in both nicotine- and saline-withdrawing rats. Thus, increasing glutamate transmission via mGlu2/3 autoreceptor blockade reduces the effects of mGlu5 receptor blockade on nicotine self-administration and MPEP-induced exacerbation of brain reward deficits associated with nicotine withdrawal.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17113075      PMCID: PMC1803080          DOI: 10.1016/j.ejphar.2006.10.011

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  53 in total

1.  Metabotropic glutamate 5 receptor antagonist MPEP decreased nicotine and cocaine self-administration but not nicotine and cocaine-induced facilitation of brain reward function in rats.

Authors:  P J Kenny; N E Paterson; B Boutrel; S Semenova; A A Harrison; F Gasparini; G F Koob; P D Skoubis; A Markou
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

2.  MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.

Authors:  Shigeyuki Chaki; Ryoko Yoshikawa; Shiho Hirota; Toshiharu Shimazaki; Maoko Maeda; Naoya Kawashima; Takao Yoshimizu; Akito Yasuhara; Kazunari Sakagami; Shigeru Okuyama; Shigetada Nakanishi; Atsuro Nakazato
Journal:  Neuropharmacology       Date:  2004-03       Impact factor: 5.250

3.  The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice.

Authors:  Neil E Paterson; Svetlana Semenova; Fabrizio Gasparini; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

4.  Mecamylamine acutely increases human intravenous nicotine self-administration.

Authors:  Jed E Rose; Frederique M Behm; Eric C Westman; James E Bates
Journal:  Pharmacol Biochem Behav       Date:  2003-09       Impact factor: 3.533

5.  Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent.

Authors:  Guy A Higgins; Theresa M Ballard; James N C Kew; J Grayson Richards; John A Kemp; Geo Adam; Thomas Woltering; Shigetada Nakanishi; Vincent Mutel
Journal:  Neuropharmacology       Date:  2004-06       Impact factor: 5.250

6.  Metabotropic glutamate receptor 5 localized in the limbic forebrain is critical for the development of morphine-induced rewarding effect in mice.

Authors:  Takeshi Aoki; Minoru Narita; Masahiro Shibasaki; Tsutomu Suzuki
Journal:  Eur J Neurosci       Date:  2004-09       Impact factor: 3.386

7.  Group II metabotropic glutamate receptor antagonists LY341495 and LY366457 increase locomotor activity in mice.

Authors:  Michael F O'Neill; Claire Heron-Maxwell; Michael W Conway; James A Monn; Paul Ornstein
Journal:  Neuropharmacology       Date:  2003-10       Impact factor: 5.250

Review 8.  The ups and downs of addiction: role of metabotropic glutamate receptors.

Authors:  Paul J Kenny; Athina Markou
Journal:  Trends Pharmacol Sci       Date:  2004-05       Impact factor: 14.819

9.  Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking.

Authors:  Michela Tessari; Maria Pilla; Michela Andreoli; Daniel M Hutcheson; Christian A Heidbreder
Journal:  Eur J Pharmacol       Date:  2004-09-19       Impact factor: 4.432

10.  Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats.

Authors:  Paul J Kenny; Fabrizio Gasparini; Athina Markou
Journal:  J Pharmacol Exp Ther       Date:  2003-06-12       Impact factor: 4.030

View more
  33 in total

1.  mGlu receptors and drug addiction.

Authors:  Richard M Cleva; M Foster Olive
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2012-01-20

2.  Involvement of metabotropic glutamate receptor 5 in brain reward deficits associated with cocaine and nicotine withdrawal and somatic signs of nicotine withdrawal.

Authors:  Astrid K Stoker; Berend Olivier; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2011-12-03       Impact factor: 4.530

Review 3.  Homers regulate drug-induced neuroplasticity: implications for addiction.

Authors:  Karen K Szumlinski; Alexis W Ary; Kevin D Lominac
Journal:  Biochem Pharmacol       Date:  2007-07-27       Impact factor: 5.858

Review 4.  Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy.

Authors:  Samuel A Barnes; Douglas J Sheffler; Svetlana Semenova; Nicholas D P Cosford; Anton Bespalov
Journal:  Biol Psychiatry       Date:  2018-03-09       Impact factor: 13.382

Review 5.  Metabotropic glutamate receptor ligands as potential therapeutics for addiction.

Authors:  M Foster Olive
Journal:  Curr Drug Abuse Rev       Date:  2009-01

6.  Nicotine withdrawal-induced inattention is absent in alpha7 nAChR knockout mice.

Authors:  K K Higa; A Grim; M E Kamenski; J van Enkhuizen; X Zhou; K Li; J C Naviaux; L Wang; R K Naviaux; M A Geyer; A Markou; J W Young
Journal:  Psychopharmacology (Berl)       Date:  2017-02-28       Impact factor: 4.530

7.  Differences in mechanisms underlying reinstatement of cigarette smoke extract- and nicotine-seeking behavior in rats.

Authors:  Sarah J Cross; Daisy D Reynaga; Michelle Cano; James D Belluzzi; Nurulain T Zaveri; Frances M Leslie
Journal:  Neuropharmacology       Date:  2019-11-06       Impact factor: 5.250

Review 8.  Future pharmacological treatments for substance use disorders.

Authors:  Ariadna Forray; Mehmet Sofuoglu
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

9.  The effects of the mGluR5 receptor antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) on behavioural responses to nicotine.

Authors:  Valeria Tronci; Svetlana Vronskaya; Nicholas Montgomery; Daniela Mura; David J K Balfour
Journal:  Psychopharmacology (Berl)       Date:  2010-04-27       Impact factor: 4.530

Review 10.  Role of the glutamatergic system in nicotine dependence : implications for the discovery and development of new pharmacological smoking cessation therapies.

Authors:  Matthias E Liechti; Athina Markou
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.